SYMQY.US SymBio Pharmaceuticals Limited

Healthcare Pharmaceuticals USA Stocks
0.4655 USD
Close of Nov 17, 2026
0.2805 0.6370
Market cap
USD 37.3M
P/E
-
P/B
2.74x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SYMQY.US undervalued?

Graham number

The Graham number of SymBio Pharmaceuticals Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SymBio Pharmaceuticals Limited fundamental analysis

No fundamental analysis for SymBio Pharmaceuticals Limited yet.

SymBio Pharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.

Full company profile